Prospective monitoring of antibody response following COVID-19 vaccination in people with Down syndrome (PRIDE study)
- Funded by Netherlands Organisation for Health Research and Development (ZonMW)
- Total publications:0 publications
Grant number: 1.04301E+13
Grant search
Key facts
Disease
COVID-19Start & end year
20212024Known Financial Commitments (USD)
$1,235,330.42Funder
Netherlands Organisation for Health Research and Development (ZonMW)Principal Investigator
Prof dr LJ BontResearch Location
NetherlandsLead Research Institution
Universitair Medisch Centrum UtrechtResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Individuals with multimorbidityOther
Occupations of Interest
Unspecified
Abstract
The risk of severe course of SARS-CoV-2 infection in people with Down Syndrome (DS) is substantially increased. The risk of death is 3-10 fold higher than in healthy people. COVID vaccines have been registered but none of them have been studied in people with DS. Vaccine responses in people with DS are suboptimal, probably related to the partial immune deficiency in DS characterized by - among other things - a lack of naïve T-cells. In this study (PRIDE), we aim to assess the immunogenicity of SARS-CoV-2 vaccination in patients with DS. OBJECTIVES Primary objective: to assess the antibody response after mRNA SARS-CoV-2 vaccination in people with Down Syndrome.